ArticleESC heart failure2025
Heart failure decompensation with cardiogenic shock exhibits distinct sequential inflammatory profiles.
Article in ESC heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Hypoperfusion-Shock Continuum in Acute Decompensated Heart Failure.Circulation. Heart failure · 2026Review
- Cardiogenic Shock: Clinical Management, Outcomes and Future Directions.Journal of cardiovascular development and disease · 2026Review
- Haemodynamic consequences of acute pulmonary embolism predict risk of CTPA-related acute kidney injury.ESC heart failure · 2025Article
- Heart failure decompensation with cardiogenic shock exhibits distinct sequential inflammatory profiles.ESC heart failure · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
aimsThe inflammatory profile of cardiogenic shock (CS) after myocardial infarction affects outcomes; however, little is known about the impact of inflammatory changes in CS caused by acute decompensated heart failure (ADHF-CS). We measured levels of inflammatory cytokines in patients with ADHF-CS admitted to a cardiac intensive care unit (CICU).
methodsWe identified patients admitted to our CICU with ADHF-CS who had consented to having biospecimens stored. We identified two comparator groups of patients with HF seen as outpatients with stored biospecimens: firstly, those who had no history of decompensation and did not develop CS during follow-up after sample acquisition (stable HF), and secondly, a group of patients who developed CS during follow-up (pre-CS). All samples underwent 48-plex cytokine and white blood cell differential testing with the differences between groups analysed by comparing means.
resultsEighty-four ADHF-CS patients were identified who had samples obtained at a median of 2 [inter-quartile range (IQR) 0-7] days after CICU admission. Thirty-six pre-CS outpatients had samples taken 137 (IQR 41-258) days before admission with CS, and 338 stable HF control patients were included. Cytokine profiles differed between ADHF-CS and stable HF. Patients with CS had higher pro-inflammatory cytokine levels [including interleukin-1 (IL-1), interleukin-6 (IL-6) and interleukin-8 (IL-8)] and total white cell counts than stable HF patients. Analysis of the pre-CS outpatient group suggested an intermediate stage in subacute transition to CS.
conclusionsADHF-CS is characterized by high levels of pro-inflammatory cytokines and total white count, compared with ambulatory HF. Decompensation from HF has two distinct inflammatory phases that may help identify outpatients at risk of CS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.